Latest news with #AssuranceMaladie
Yahoo
6 days ago
- Business
- Yahoo
InsuJet Distribution Expands Across France
NuGen Medical Devices Launches French InsuJet(TM) e-Commerce Platform, Delivering Needle-Free Insulin with On-Demand Clinical Support Toronto, Ontario--(Newsfile Corp. - July 7, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, today unveiled — a dedicated French-language information and e-commerce site for InsuJet™, the Company's needle-free insulin-delivery device. Developed with NuGen's exclusive distributor Sol-Millennium France, the platform gives people living with diabetes in France instant access to product details, educational resources, and secure online purchasing. At checkout, patients may opt for nurse-led onboarding that supports them all the way to seamless enrolment in the recurring consumables program — ensuring confident adoption and lasting adherence. A Growing Market Need According to France's National Health Insurance (Assurance Maladie), diabetes remains a critical — and growing — public-health challenge: in 2022, 4.33 million people were living with diabetes — a prevalence of 6.3 percent. The economic impact is escalating just as quickly: reimbursements tied to diabetes jumped from €7.6 billion in 2015 to more than €10 billion in 2022.1 Complications accounts for a significant share of diabetes-related healthcare costs because most of the 92 % of patients who have type 2 diabetes delay insulin start; 80 % of French physicians blame needle anxiety. By eliminating the needle for France's ~4 million type 2 diabetics, InsuJet™ promotes earlier insulin use and delivers substantial savings to the national health system.2 These figures highlight the urgent need for innovative, cost-effective solutions such as InsuJet's needle-free insulin-delivery technology. About InsuJet™ Designed for adults and children (age 6+), InsuJet™ delivers standard U-100 insulin via a precise high-pressure micro-jet through the nozzle that penetrates the skin without needles. Users experience less anxiety, no sharps-disposal burden, and simpler day-to-day diabetes management. Clinical studies demonstrate faster insulin absorption, tighter glycaemic control, and higher patient satisfaction versus traditional needles - advances that directly address France's call for safer, more economical diabetes care. Key Features: Durability — reusable for up to 5,000 injections (≈ 3.5 years at four injections per day) Universally compatible — works with any U-100 insulin in 3 mL cartridges, prefilled insulin pens, or 10 mL vials Needle-free convenience — eliminates sharps containers and related waste CE marked — compliant with European medical-device standards Broad usability — approved for adults and children aged six and over Adoption and Interest from the Clinical Community: The healthcare community has responded enthusiastically to the introduction of InsuJet™. Officially pre-launched at the 2025 Congress of the Société Francophone du Diabète (SFD) this past April, where it was named Innovation of the Year in Insulin Therapy, InsuJet™ attracted significant clinical interest. Numerous hospitals requested demonstrations, leading to two clinical evaluations at the Institut de Diabétologie et Nutrition du Centre (IDNC). These studies aim to support national reimbursement and further validate the clinical and economic benefits of needle-free insulin delivery. About NuGen Medical Devices NuGen develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship InsuJet™ system is approved in 42 countries and is designed to improve the lives of millions of people with diabetes worldwide. About Sol-Millennium Medical Group Sol-Millennium Medical Group is a vertically integrated manufacturer of medical devices. With global operations and a commitment to deliver advanced, patient-centric healthcare technologies, Sol-Millennium Medical partners with healthcare providers to improve outcomes and build a healthier tomorrow for all. Websites: | | / X: @NuGenMD | LinkedIn: NuGenMDInvestor Relations: IR@ For further information, please contact: Liang Lin, Chief Executive Officer+1 (833) 285-2666ir@ Notice Regarding Forward-Looking Information: Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release. This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. 1 To view the source version of this press release, please visit
Local France
18-02-2025
- Health
- Local France
Carte vitale, sugar tax and prescriptions - What changes in France's 2025 health budget
It's been a rocky ride, politically, but now France has finalised its spending plans for 2025 - you can find a breakdown of the main part of the budget HERE, including VAT changes, tax hikes for big businesses and high earners and an increased 'eco tax' on plane tickets. The health and social care plans are contained in a separate spending plan known as the Budget de la Sécu. From changes to patient transport and sick pay, via an extra sugar tax and the ability of doctors to charge patients who make an appointment and don't show up, here's what it contains. Health budget The total health budget for 2025 is €265.9 billion, a 3.4 percent increase on last year. That includes an extra €1 billion for the total hospital budget, and a €300 million 'emergency fund' for Ehpads (care homes and nursing homes). However Assurance Maladie - the state health insurance responsible for refunding patients costs for things like medical appointments, prescriptions and treatment, will be expected to find a total of €4.3 billion in savings. Prime minister François Bayrou has also promised a 'debate' on pricing by mutuelle companies (the extra top-up health insurance that most people in France have). It has been alleged that mutuelle companies have already hiked the price of their premiums in anticipation of extra costs in the 2025 Budget, which did not in fact take place. The companies deny this. Taxes The budget also contains extra taxes on sugar, especially sugary drinks, and gambling. An extra tax will be applied to lottery tickets, scratchcards and online gambling from July 1st, and to drinks with high levels of sugar from January 1st 2026. The budget also contains a provision for a ' taxe lapin ' - this isn't technically a tax, it's the proposal for doctors to charge a fee to patients who make an appointment and then don't either show up or cancel. The name comes from the French phrase 'poser un lapin', which means to stand somebody up or to be a no-show. The exact details of any such fee are set to be revealed later in a decree. Prescriptions Certain prescription drugs or treatments which are especially expensive - the exact list to be compiled after a consultation - will require doctors to request permission in advance. Doctors will have to fill in a form detailing why the drug is necessary in this case and why a cheaper alternative cannot be used. If the drug is approved then the state will continue to reimburse it, if it is not approved then the doctor can still prescribe it, but the patient would have to pay the entire cost themselves. Digital carte vitale The plan has been under discussion for a long time, but the 2025 Budget give the go-ahead for a digital version of the carte vitale - the health card that allows people who are registered in the French health system to have their medical costs reimbursed by the state. The digital version of the card will be optional, for those who want it, and physical cards will remain in use - more details HERE. Lowering of sick pay rates The portion of sick pay paid by the government (as opposed to the part paid by the employer) will be lowered - going from a maximum of 1.8 times the Smic (French minimum wage) to 1.4 times. The rest will be paid by the employer. Patient transport In France patients can request transport to medical appointments if they are unable to drive or use public transport, and this is often provided by taxis which have an agreement with healthcare providers. Plans to cut the rate that drivers can charge for patient transport had already led to strikes and roadblocks by taxi drivers. The budget seeks to compromise on the issue - saying that €300 million in savings must be made in patient transport costs, but leaving details of agreements up to local authorities and taxi companies. If savings are not made, Assurance maladie will be able to lower the rates, and can also refuse agreements with new taxi companies if there are already enough providers in a certain area.
